JUN 13, 2024
Ultrasensitive circulating tumor DNA (ctDNA) detection appears to improve the clinical sensitivity of minimal residual disease (MRD) at key landmarks in early stage non-small cell lung cancer (NSCLC), researchers reported at the 2024 ASCO Annual Meeting.
“PhasED-Seq detected MRD at levels below one ppm and was associated with significantly better outcomes, revealing potential benefits of adjuvant therapy in patients with MRD+. This suggests that ultrasensitive MRD detection is promising for use in risk-adapted trials in early stage NSCLC,” James M. Isbell, MD, MSCI, and colleagues wrote in the abstract of their poster presentation.
Read the full article on physiciansweekly.com